SRSF2 and acute myeloid leukemia: The absence of KIT mutations necessitates a thorough evaluation for other genetic abnormalities, such as mutations in ASXL1, RUNX1, and SRSF2, which are known to impact prognosis and survival in SM-AML adversely [25].